Curated News
By: NewsRamp Editorial Staff
December 20, 2024

Mainz Biomed N.V. Moves Closer to U.S. Debut of ColoAlert® for Early Cancer Detection

Reddit Discuss on RedditDiscuss on LinkedIn LinkedInDiscuss on Substack SubstackDiscuss on Telegram Telegram
Source News Release

TLDR

  • Mainz Biomed N.V. is moving closer to commercializing its early colorectal cancer detection screening ColoAlert® in the U.S. by inking deals with Quest Diagnostics and Thermo Fisher Scientific.
  • ColoAlert is an early detection screening that spots bleeding and non-bleeding tumors through tumor DNA analysis, with sensitivities exceeding 90% for detecting colorectal cancer and over 80% for advanced adenomas.
  • ColoAlert, if approved, may help rectify the lack of timely screening for colorectal cancer, potentially saving lives and improving public health outcomes.
  • Mainz Biomed's recent strategic alliances with Quest Diagnostics and Thermo Fisher Scientific represent a monumental step forward in transforming cancer prevention and healthcare solutions.

Impact - Why it Matters

The potential U.S. debut of ColoAlert® has significant implications for public health, offering a less invasive and easy-to-use early cancer detection solution. If successful, it could help address the lack of timely screening for colorectal cancer and potentially improve survival rates. This news underscores the importance of innovative diagnostic solutions in advancing public health outcomes and the significant market opportunity for Mainz Biomed in the U.S.

Summary

Mainz Biomed N.V. (NASDAQ: MYNZ) is close to launching its early colorectal cancer detection screening ColoAlert® in the U.S. through partnerships with Quest Diagnostics (NYSE: DGX) and Thermo Fisher Scientific (NYSE: TMO). Quest Diagnostics will provide clinical trial and laboratory services for Mainz's FDA pivotal study of ColoAlert, while Thermo Fisher will contribute its expertise and infrastructure. If approved, ColoAlert will target millions of Americans at risk of colorectal cancer. The product is less invasive and easy to use, potentially addressing the gap in timely colorectal cancer screening in the U.S.

Source Statement

This curated news summary relied on this press release disributed by News Direct. Read the source press release here, Mainz Biomed N.V. Moves Closer to U.S. Debut of ColoAlert® for Early Cancer Detection

blockchain registration record for the source press release.